Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Abstract
Severe bone loss commonly occurs in individuals with chronic spinal cord injury who are non-weight-bearing and leads to an increased risk of lower extremity fractures. This 12 month, multi-site, double-blind, randomized, placebo-controlled study evaluates the efficacy and safety of two interventions known to be anabolic to bone, parathyroid hormone and mechanical loading (provided as teriparatide and vibration, respectively) in 60 SCI individuals with low bone mass. 56 out of 60 participants (retention rate of 93 ) completed the initial treatment period (1 year); 24 of 25 participants who elected to enter a 1 year open-label extension of teriparatide therapy have recently completed. No safety issues have arisen during the course of the study. The data from the first year of treatment show no statistically significant difference among the 3 treatment groups in bone density or bone strength at any skeletal site despite bone marker data demonstrating a metabolic response to teriparatide but not to vibration alone. Results from the second year of treatment are not yet available.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2015
- Accession Number
- AD1010535
Entities
People
- Thomas J Schnitzer
Organizations
- Northwestern University